Yi Li is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 24 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8329 Brimhall Rd Ste 801
Bakersfield, CA 933122243
Telephone
661-695-8385Provider last certified this registry record 12 May 2020.
Clinical trials
- RCT Comparing Remimazolam With Propofol Under EEG DSA Guidance During Cardiac Electrophysiology Studies and Ablation
Sponsor: Taipei Veterans General Hospital, Taiwan
- Mirror Therapy Combined With Task- vs. Impairment-oriented Rehabilitation Program
Sponsor: I-Shou University
- Effectiveness of Online Program and Task-related Training for Parkinson's Disease
Sponsor: Chang Gung University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
38 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202548 payments
- Amgen Inc.Program year202547 payments
- Novartis Pharmaceuticals CorporationProgram year202529 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
72.6%TNF inhibitor40.9%Golimumab48%Certolizumab pegol44%Infliximab8%Enbrel Sureclick0%Humira(Cf) Pen0%Enbrel Mini0%Cimzia (2 Pack)0%Part D + Part B<11 patientsInterleukin-6 Receptor Antagonist13.2%Tocilizumab100%Part B, office-administered≥13 patients+ 6 more classes in this area
Musculoskeletal
21.6%RANK Ligand Inhibitor11.8%Denosumab100%Part B, office-administered≥196 patientsOther drugs affecting bone structure and mineralization9.7%Romosozumab-aqqg100%Part B, office-administered≥19 patients+ 3 more classes in this area
Dermatology
4.7%Corticosteroid4.7%Methylprednisolone acetate63%Methylprednisolone sodium succinate37%Methylprednisolone0%Part D + Part B<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
6 NIH research awards on record, funded 2002–2026 per NIH RePORTER. The latest:
6 awards on record per NIH RePORTER; the itemized rows are on their way. Why? →
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”